Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Value in Health Regional Issues|April 29, 2018
Economic Burden of Individual Suffering from Atrial Fibrillation-Related Stroke in ChinaShanlian Hu, Lin Zhan, Bao Liu, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 11, 2014
Estimated public health impact of nationwide vaccination of infants with 7-valent pneumococcal conjugate vaccine (PCV7) in ChinaShanLian Hu, Qiang Shi, Chieh-I Chen, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 25, 2007
An Asian regional analysis of cost-effectiveness of early irbesartan treatment versus conventional antihypertensive, late amlodipine, and late irbesartan treatments in patients with type 2 diabetes, hypertension, and nephropathyLieven Annemans, Nadia Demarteau, Shanlian Hu, et al.
Value in Health Regional Issues|April 29, 2018
Guidance Document: Global Pharmacoeconomic Model Adaption StrategiesC Daniel Mullins, Nneka C Onwudiwe, Gabriela Tannus Branco de Araújo, et al.
Frontiers in Public Health|September 12, 2025
Quality of life and its contributors among patients with homozygous familial hypercholesterolemia in ChinaMi Tang, Ziping Ye, Xueyan Zhang, et al.
Value in Health Regional Issues|April 29, 2018
Estimating the Cost-Effectiveness of the 7-Valent Pneumococcal Conjugate Vaccine in Shanghai, ChinaShanlian Hu, Qiang Shi, Shengfan Song, et al.
Pharmacoeconomics - Open|March 10, 2023
Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in ChinaShanlian Hu, Zhiliu Tang, James P Harrison, et al.
Bioscience Trends|August 23, 2019
Overview on social security system of rare diseases in ChinaJiangjiang He, Peipei Song, Qi Kang, et al.
BMC Medical Research Methodology|August 5, 2022
Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81-8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare settingRong Chen, Dmitry Gultyaev, Johanna Lister, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 4, 2009
Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR Drug Cost Task Force report--Part VILizheng Shi, Meredith Hodges, Michael Drummond, et al.
Pageof 4